A novel , fully bacterially produced recombinant virus-like particle ( VLP ) based influenza vaccine ( gH@-Qbeta ) against A/California/@ / @ ( H@N@ ) was tested in a double-blind , randomized phase I clinical trial at two clinical sites in Singapore .